title: Statin treatment following coronary artery stenting and one-year survival.
abstract: OBJECTIVE
  We assessed the influence of statin therapy given after the procedure on one-year survival of patients treated with coronary artery stenting.
  
  
  BACKGROUND
  Coronary artery stenting is currently a common treatment option for patients with symptomatic coronary artery disease (CAD). Although several secondary prevention trials have demonstrated improved survival achieved with statin therapy in conservatively treated patients with CAD, it is not known whether this benefit can also be expected in patients undergoing percutaneous coronary interventions with intraluminal stenting.
  
  
  METHODS
  This study included 4,520 patients younger than 80 years who underwent coronary artery stenting and were discharged from the hospital in the period October 1995 through September 1999. We compared one-year mortality of 3,585 patients who received statins after stenting with that of 935 patients who did not.
  
  
  RESULTS
  The mortality rate at one year was 2.6% among patients who received statins and 5.6% among those who did not. Thus, statin therapy at discharge was associated with an unadjusted odds ratio (OR) of 0.46 (95% confidence interval [CI], 0.33 to 0.65), indicating a 54% reduction in the risk of death at one year. After adjusting for other covariates, the risk reduction associated with statin therapy was 49%, OR 0.51 (95% CI, 0.36 to 0.71). This reduction was observable in most of the subgroups of patients.
  
  
  CONCLUSIONS
  The results of this nonrandomized study show that statin therapy improves survival after coronary artery stenting independent of patient characteristics recorded on the day of the intervention.
authors.affiliation: Deutsches Herzzentrum and 1. Medizinische Klinik rechts der Isar, Technische Universität, Munich, Germany. aschoemig@dhm.mhn.de
authors.forename: Albert
authors.initials: A
authors.lastname: Schömig
authors.forename: Julinda
authors.initials: J
authors.lastname: Mehilli
authors.forename: Heidrun
authors.initials: H
authors.lastname: Holle
authors.forename: Karin
authors.initials: K
authors.lastname: Hösl
authors.forename: Dorejd
authors.initials: D
authors.lastname: Kastrati
authors.forename: Jürgen
authors.initials: J
authors.lastname: Pache
authors.forename: Melchior
authors.initials: M
authors.lastname: Seyfarth
authors.forename: Franz-Josef
authors.initials: FJ
authors.lastname: Neumann
authors.forename: Josef
authors.initials: J
authors.lastname: Dirschinger
authors.forename: Adnan
authors.initials: A
authors.lastname: Kastrati
mesh_terms: D003324:Coronary Artery Disease / Q000401:mortality / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017035:Pravastatin / Q000627:therapeutic use*; D019821:Simvastatin / Q000627:therapeutic use*; D015607:Stents; D015996:Survival Rate
chemical_list: D019821:Simvastatin; D017035:Pravastatin